<DOC>
	<DOC>NCT00696904</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333 in healthy volunteers and the antiviral activity in HCV infected subjects.</brief_summary>
	<brief_title>Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects</brief_title>
	<detailed_description>Phase 1, double-blind, randomized, placebo-controlled clinical trial in healthy and HCV genotype 1 infected adults to evaluate safety, tolerability, antiviral activity and pharmacokinetics of ABT-333.</detailed_description>
	<criteria>Main Selection Criteria for Healthy Volunteers: Subject has provided written consent. Subject is in general good health. If female, subject is postmenopausal. If female, subject is not pregnant and is not breastfeeding. Main Selection Criteria for HCV+ Subjects: Subject is HAVIgM, HBsAg or HIV Ab negative. Subject is HCV genotype 1 with HCV RNA of &gt; 50,000 IU/mL. Subject is excluded if they have previously received antiviral therapy for HCV infection Subjects must demonstrate chronic hepatitis C infection for at least 6 months prior to study enrollment Subjects must have a prior liver biopsy with histology consistent with HCV induced liver damage, and with no evidence of cirrhosis or liver pathology due to any cause other than chronic HCV. See above for main selection criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>